Soleno Therapeutics, Inc. (NASDAQ: SLNO) reported Q3 EPS of $0.47, $0.42 better than the analyst estimate of $0.05. Revenue for the quarter came in at $66 million versus the consensus estimate of $47.46 million.

For earnings history and earnings-related data on Soleno Therapeutics, Inc. (SLNO) click here.